The effect of attenuated vaccinia virus AS strain on multiple myeloma; a case report.
The case of a 67-year-old male with IgA multiple myeloma successfully treated with AS strain of vaccinia virus is reported. The intravenous injection of this virus strain caused a definite decrease in the levels of monoclonal IgA from 1,309 mg/dl in the early stage of the treatment to 432 mg/dl on the 96th day of the regime. NK cell activity rose from 20.0% on the 10th day to 33% on the 106th day of the treatment. No adverse effects were observed throughout the entire course of the treatment. These results strongly suggest that AS strain vaccinia virus is a most promising and safe agent for the treatment of human malignancy. The possible mechanism of the beneficial effects of this virus strain is also briefly discussed.
D000368:Aged; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007167:Immunotherapy; D007694:Killer Cells, Natural / Q000276:immunology; D008297:Male; D009101:Multiple Myeloma / Q000276:immunology / Q000628:therapy*; D014613:Vaccines, Attenuated; D014616:Vaccinia virus / Q000276:immunology*; D014765:Viral Vaccines / Q000627:therapeutic use*
D007070:Immunoglobulin A; D014613:Vaccines, Attenuated; D014765:Viral Vaccines